A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Rachelle S. Doody; Rema Raman; Martin R. Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Feng He; Xiaoying Sun; Ronald G. Thomas; Paul Aisen; Eric Siemers; Gopalan Sethuraman; Richard C. Mohs

doi:10.1056/nejmoa1210951

Abstract

As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)

Keywords

PlaceboMedicineAlzheimer's diseaseInternal medicineRandomizationDiseaseCognitionClinical trialPsychiatryPathology

MeSH Terms

Activities of Daily LivingAgedAlanineAlzheimer DiseaseAmyloid Precursor Protein SecretasesAmyloid beta-PeptidesAzepinesBiomarkersCognitionDouble-Blind MethodFemaleHumansMaleMiddle AgedSkin NeoplasmsTreatment FailureWeight Loss

Affiliated Institutions

Related Publications

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner , Silvio E. Inzucchi , John M. Lachin +7 more

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...

2016 New England Journal of Medicine 3470 citations

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck , Chad J. Swanson , Paul Aisen +16 more

Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was...

2022 New England Journal of Medicine 4288 citations

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman , Christoph Wanner , John M. Lachin +9 more

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascul...

2015 New England Journal of Medicine 11369 citations

Donanemab in Early Alzheimer’s Disease

Mark A. Mintun , Albert Lo , Cynthia Evans +10 more

In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo a...

2021 New England Journal of Medicine 1451 citations

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

André C. Kalil , Thomas F. Patterson , Aneesh K. Mehta +57 more

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably amon...

2020 New England Journal of Medicine 1863 citations

Publication Info

Year: 2013
Type: article
Volume: 369
Issue: 4
Pages: 341-350
Citations: 1183
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1183

OpenAlex

Influential

1036

CrossRef

Cite This

APA Style

                            
                                
                                    Rachelle S. Doody, 
                                
                                    Rema Raman, 
                                
                                    Martin R. Farlow
                                
                                et al.
                            
                            (2013). 
                            A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. 
                            New England Journal of Medicine
                            , 369
                            (4)
                            , 341-350.
                            https://doi.org/10.1056/nejmoa1210951
                        

Identifiers

DOI: 10.1056/nejmoa1210951
PMID: 23883379

Data Quality

Data completeness: 86%